000 01441 a2200385 4500
005 20250515061358.0
264 0 _c20070411
008 200704s 0 0 eng d
022 _a1744-7623
024 7 _a10.1517/14728214.12.1.113
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGilron, Ian
245 0 0 _aEmerging drugs in neuropathic pain.
_h[electronic resource]
260 _bExpert opinion on emerging drugs
_cMar 2007
300 _a113-26 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAdenosine
_xagonists
650 0 4 _aAnalgesics
_xtherapeutic use
650 0 4 _aAnalgesics, Opioid
_xtherapeutic use
650 0 4 _aAnimals
650 0 4 _aAnticonvulsants
_xtherapeutic use
650 0 4 _aCannabinoids
_xtherapeutic use
650 0 4 _aCatecholamines
_xagonists
650 0 4 _aClinical Trials as Topic
650 0 4 _aCyclooxygenase Inhibitors
_xtherapeutic use
650 0 4 _aExcitatory Amino Acid Antagonists
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aNeuralgia
_xdrug therapy
650 0 4 _aNicotinic Agonists
_xtherapeutic use
650 0 4 _aNicotinic Antagonists
_xtherapeutic use
650 0 4 _aTRPV Cation Channels
_xagonists
700 1 _aCoderre, Terence J
773 0 _tExpert opinion on emerging drugs
_gvol. 12
_gno. 1
_gp. 113-26
856 4 0 _uhttps://doi.org/10.1517/14728214.12.1.113
_zAvailable from publisher's website
999 _c16911236
_d16911236